Call for the next generation of talents within the interdisciplinary PhD program PharMetrX

The Graduate Research Training Program PharMetrX: Pharmacometrics & Computational Disease Modelling is an interdisciplinary PhD program bridging mathematics & pharmacy. PharMetrX aims at understanding the drug-patient-disease interaction by analysing data of drug concentration, effect & disease profiles of pre-/clinical trials and of therapeutic care by developing and applying pharmacometric (i.e. PK, PD, disease) mathematical & statistical models.

We are currently inviting applications to enrol in the PharMetrX Research+ Program or the PharMetrX Training+ Program.

The PharMetrX Research+ Program (Research & Training & Network) comprises an excellent research environment in the vibrant Berlin/Potsdam area, fascinating and innovative research projects in a highly relevant field, truly transdisciplinary working groups and supervision, an individual mentorship from one of the associated industry partner consortium, a specifically tailored training program of compact academic and industry modules, a network of 133 peers and a competitive 3.5 years fellowship.

The PharMetrX Training+ Program (Training & Network) offers a specifically tailored training program of compact academic and industry modules that convey the foundations in pharmacokinetics & pharmacodynamics, systems biology, statistics, methodological approaches of modelling & simulation etc. as well as a network of 133 peers. It is open for PhD students who have started their PhD after 06 September 2025 in the field of pharmacometrics or will do so soon.

Both programs are open to candidates with a university degree in pharmacy, pharmaceutical sciences, mathematics/statistics, bioinformatics, life sciences or medicine: see https://www.PharMetrX.de and https://www.linkedin.com/company/pharmetrx.

Deadline for applications: 06 September 2026.

Start of Module Curriculum: March 2027

PharMetrX is a joint program of Freie Universität Berlin and the Universität Potsdam, supported by a consortium of global research-driven pharmaceutical companies.

Charlotte Kloft & Wilhelm Huisinga

Program Chairs